There are 2137 resources available
406MO - Sequencing paired tumor DNA and white blood cells (WBCs) increases sensitivity to track plasma circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in localized colon cancer (CC)
Presenter: Noelia Tarazona
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
87MO - Assessing tumour fraction of CSF cfDNA improves diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis (BCLM)
Presenter: Amanda Fitzpatrick
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
LBA10 - Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types
Presenter: Leonie Voorwerk
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
88MO - T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
Presenter: Marcus Schmidt
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1931MO - A HER3/DUSP6 loop determines sensitivity to HER2-targeted therapies in breast cancer
Presenter: Majid Momeny
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1932MO - Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients
Presenter: Marzia Del Re
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1933MO - TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies
Presenter: Marta Palafox
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1621MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
Presenter: Robin Jones
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1622MO - Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Presenter: John Zalcberg
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast